Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.
Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept. We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68). The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months. Besides polymorphisms rs928655 (GBP6) and rs2546890 (IL12B) were associated to response at 6 months. Nevertheless, these biomarkers should be validated in large-scale studies before its implementation in clinical practice.